scholarly journals Concern for Another’s Distress in Toddlers at High and Low Genetic Risk for Autism Spectrum Disorder

2015 ◽  
Vol 45 (11) ◽  
pp. 3594-3605 ◽  
Author(s):  
Susan B. Campbell ◽  
Nina B. Leezenbaum ◽  
Emily N. Schmidt ◽  
Taylor N. Day ◽  
Celia A. Brownell
2019 ◽  
Vol 51 (3) ◽  
pp. 431-444 ◽  
Author(s):  
Jakob Grove ◽  
◽  
Stephan Ripke ◽  
Thomas D. Als ◽  
Manuel Mattheisen ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Yaowaluck Hongkaew ◽  
Andrea Gaedigk ◽  
Bob Wilffert ◽  
Roger Gaedigk ◽  
Wiranpat Kittitharaphan ◽  
...  

We investigated the association between genetic variations in pharmacodynamic genes and risperidone-induced increased prolactin levels in children and adolescents with autism spectrum disorder (ASD). In a retrospective study, variants of pharmacodynamic genes were analyzed in 124 ASD patients treated with a risperidone regimen for at least 3 months. To simplify genotype interpretation, we created an algorithm to calculate the dopamine D2 receptor (DRD2) gene genetic risk score. There was no relationship between prolactin levels and single SNPs. However, the H1/H3 diplotype (A2/A2-Cin/Cin-A/G) of DRD2/ankyrin repeat and kinase domain containing 1 (ANKK1) Taq1A, DRD2 -141C indel, and DRD2 -141A>G, which had a genetic risk score of 5.5, was associated with the highest median prolactin levels (23 ng/ml). As the dose-corrected plasma levels of risperidone, 9-OH-risperidone, and the active moiety increased, prolactin levels in patients carrying the H1/H3 diplotype were significantly higher than those of the other diplotypes. DRD2 diplotypes showed significantly high prolactin levels as plasma risperidone levels increased. Lower levels of prolactin were detected in patients who responded to risperidone. This is the first system for describing DRD2 haplotypes using genetic risk scores based on their protein expression. Clinicians should consider using pharmacogenetic-based decision-making in clinical practice to prevent prolactin increase.


Author(s):  
Jarle Johannessen ◽  
Terje Nærland ◽  
Sigrun Hope ◽  
Tonje Torske ◽  
Anett Kaale ◽  
...  

AbstractClinical relevance of genetic testing is increasing in autism spectrum disorder (ASD). Information about genetic risk may contribute to improved diagnostics, treatment and family planning, but may also be perceived as a burden. Knowledge about the families’ preferences with regard to genetic risk information is important for both health care professionals and policy makers. We investigated attitudes towards sharing information about genetic risk of ASD and knowledge about future health among parent members of the Norwegian Autism Association (N = 1455) using a questionnaire, and the relationships with parent and child characteristics, such as age, gender and ASD severity. Most preferred autonomy in deciding whom to inform about genetic risk of ASD (74.4%) and a minority supported extensive intra-familial disclosure of the genetic risk (41.1%). The majority agreed that it is an obligation to know as much as possible relevant for future health (58.0%) and only 51.7% agreed to a principle of a ‘right not to know’. In regression models, the attitudes were associated with opinions about benefits and harms of genetic testing (e.g., treatment, family planning, understanding of ASD pathology, insurance discrimination and family conflict). In sum, the findings show that most parents want to know as much as possible relevant for their children’s future health and keep their autonomy and intra-familial confidentiality about genetic risk information. Nearly half of the parents were not concerned with a “right not to know”. These attitudes can inform development of guidelines and bioethics in the age of genomic precision medicine.


2016 ◽  
Vol 46 (7) ◽  
pp. 2305-2316 ◽  
Author(s):  
Susan B. Campbell ◽  
Nina B. Leezenbaum ◽  
Amanda S. Mahoney ◽  
Elizabeth L. Moore ◽  
Celia A. Brownell

2018 ◽  
Vol 49 (4) ◽  
pp. 1366-1377 ◽  
Author(s):  
Susan B. Campbell ◽  
Amanda S. Mahoney ◽  
Celia A. Brownell ◽  
Elizabeth L. Moore ◽  
Amy B. Tavares

Autism ◽  
2014 ◽  
Vol 19 (8) ◽  
pp. 915-924 ◽  
Author(s):  
Susan B Campbell ◽  
Nina B Leezenbaum ◽  
Amanda S Mahoney ◽  
Taylor N Day ◽  
Emily N Schmidt

Sign in / Sign up

Export Citation Format

Share Document